US Federal House Bill HB842

US Federal 2025-2026 Regular Session

• Introduced: 1/31/25
• Refer: 1/31/25
• Report Pass: 9/17/25

Caption

Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Impact

If passed, HB842 would potentially make significant changes to the existing framework of Medicare by ensuring that beneficiaries have access to advanced screening technologies that can detect cancers early, when they are typically more treatable. The act implicitly encourages the development of innovative cancer screening tests through its stipulations for what constitutes a 'multi-cancer early detection screening test'. This inclusion may encourage research and investment in technologies aimed at improving cancer outcomes while ensuring that seniors have better opportunities for early diagnosis.

Summary

House Bill 842, known as the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, seeks to amend the Social Security Act to provide Medicare coverage for multi-cancer early detection screening tests. This bill offers a provision for these tests to be covered starting January 1, 2028, which are designed to facilitate the concurrent detection of multiple cancer types across various organ sites. By implementing this coverage, the bill aims to enhance preventative healthcare measures for individuals eligible for Medicare, reinforcing early detection as a key strategy in combating cancer-related mortality rates.

Contention

As always with healthcare legislation, there may be contention surrounding the implementation and funding aspects of HB842. Opposition may emerge concerning the cost of expanding Medicare coverage, particularly how it would be financed and the potential impacts on other Medicare services. There are also questions regarding the efficacy and accuracy of multi-cancer screening tests, which could affect the debate on whether the benefits of such screenings outweigh potential risks. Additional discussions might address whether this expanded coverage could lead to over-testing or misdiagnosis, thus raising awareness about the need for clear guidelines on the appropriate use of these tests.

Congress_id

119-HR-842

Policy_area

Health

Introduced_date

2025-01-31